UCB sells anti-haemorrhagic drug to Eumedica but doubts persist over long-term strategy
This article was originally published in Scrip
Executive Summary
UCBhas sold the worldwide rights to its anti-haemorrhagic drug Somatostatine-UCB (somatostatin) to Eumedica for around €22 million, analysts estimate.